Drug intelligence / Profile preview

BIOXPACE

Development stage: Preclinical
Lead developer: Bioscience Institute
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cell Therapies
Administration: Intravenous, Topical, Intradermal

Overview

BIOXPACE is a regenerative medicine offering developed by the Bioscience Institute, focusing on the therapeutic application of exosomes derived from mesenchymal stem cells (MSCs). It is utilized primarily in the context of anti-aging and regenerative therapies. The mechanism involves the delivery of exosomal cargo—including proteins, lipids, and nucleic acids—to target cells, facilitating intercellular communication and promoting tissue repair and rejuvenation. BIOXPACE is often marketed alongside CELLSKILL, the company's stem cell expansion service, as part of a comprehensive suite of regenerative medicine services offered at their clinical centers.

Brand names: BIOXPACE

Beyond the preview

Go deeper on BIOXPACE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOXPACE.

Explore the full profile